The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Alnylam Pharmaceuticals Inc

Nasdaq: ALNY
Last

(U.S.) $132.33

Today's change+0.32 +0.24%
Updated November 22 4:00 PM EST. Delayed by at least 15 minutes.
 

Alnylam Pharmaceuticals Inc

Nasdaq: ALNY
Last

(U.S.) $132.33

Today's change+0.32 +0.24%
Updated November 22 4:00 PM EST. Delayed by at least 15 minutes.

Alnylam Pharmaceuticals Inc up (U.S.)$0.32

Alnylam Pharmaceuticals Inc closed up Wednesday by (U.S.)$0.32 or 0.24% to (U.S.)$132.33. Over the last five days, shares have gained 5.07% and 253.45% year to date. Shares have outperformed the S&P 500 by 171.99% during the last year.

Key company metrics

  • Open(U.S.) $131.45
  • Previous close(U.S.) $132.01
  • High(U.S.) $133.47
  • Low(U.S.) $129.35
  • Bid / Ask(U.S.) $129.50 / (U.S.) $0.00
  • YTD % change+253.45%
  • Volume771,751
  • Average volume (10-day)1,443,040
  • Average volume (1-month)1,271,088
  • Average volume (3-month)1,290,287
  • 52-week range(U.S.) $35.98 to (U.S.) $147.63
  • Beta2.96
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$5.25
Updated November 22 4:00 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-664.70%

Although this company's net profit margin is negative, it is above the industry average and implies that Alnylam Pharmaceuticals Inc is operating more effectively than other companies in the industry.
Company Books

S&P TSX0.02%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2017Q2/2017Q1/2017Q4/2016
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201709/30/2017Jun 30, 201706/30/2017Mar 31, 201703/31/2017Dec 31, 201612/31/2016
Revenue17161917
Total other revenue--------
Total revenue17161917
Gross profit--------
Total cost of revenue--------
Total operating expense143136125133
Selling / general / administrative48463828
Research & development959187105
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-126-120-107-115
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax-123-118-107-113
Income after tax-123-118-107-113
Income tax, total------0
Net income-123-118-107-113
Total adjustments to net income--------
Net income before extra. items-123-118-107-113
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-123-118-107-113
Inc. avail. to common incl. extra. items-123-118-107-113
Diluted net income-123-118-107-113
Dilution adjustment--------
Diluted weighted average shares92888686
Diluted EPS excluding extraordinary itemsvalue per share-1.34-1.34-1.25-1.32
Dividends per sharevalue per share0.000.000.00--
Diluted normalized EPSvalue per share-1.34-1.34-1.25-1.32